Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-06 04:14:16 - browse：622

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Commercial surrogacy can be ethical, despite pope’s claims

WSS

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

General Catalyst, Summa Health deal will turn on physician buy

Readout LOUD podcast: How biotech is using artificial intelligence

Doctors' information doesn't help them choose wisely when sick

explore

Wikipedia

focus

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: How biotech is using artificial intelligence

Malaria cases in Florida and Texas: Here’s what you need to know

Some dementia cases could be undiagnosed liver disease

Guidelines to prevent youth baseball injuries need more muscle

Key House Republican on health care plans exit from Congress

Hepatitis C has a cure — but many Americans still lack access to it

Novo Nordisk to expand supply of Wegovy for U.S. patients

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Cognito secures funding to test medical device for Alzheimer's

focus

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

New Ultima Genomics DNA sequencer can read genome for $100

What should King Charles tell the public about his cancer?

What we need to know about Arena Bioworks

Commercial surrogacy can be ethical, despite pope’s claims

For Medicare Advantage, Democrats want stronger protections around AI

focus

hotspot

focus

leisure time